Scarica l'app Stockscreener
13.10
0.23%
-0.02
Dopo l'orario di chiusura:
13.10
Syndax Pharmaceuticals Inc Borsa (SNDX) Ultime notizie
Syndax at Barclays Healthcare Conference: Strategic Vision for Menin Inhibitors - Investing.com UK
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
Syndax Pharmaceuticals’ SWOT analysis: stock soars on FDA approvals, faces profitability hurdles - Investing.com India
Graft Versus Host Disease Market Expected to rise, 2034 | Biocon, medac GmbH, MaaT Pharma, ElsaLys Biotech, Glia, Syndax Pharmaceuticals, ASC Therapeutics, SCM Lifescience, REGiMMUNE, Roche, VectivBio - The Globe and Mail
Candriam S.C.A. Cuts Stock Holdings in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat
What Does Syndax Pharmaceuticals Inc’s (NASDAQ: SNDX) Future Hold? - Stocks Register
What is B. Riley's Forecast for SNDX Q3 Earnings? - MarketBeat
What is HC Wainwright's Forecast for SNDX FY2025 Earnings? - MarketBeat
What is HC Wainwright's Forecast for SNDX Q1 Earnings? - MarketBeat
Q1 Earnings Forecast for SNDX Issued By B. Riley - MarketBeat
Syndax Pharmaceuticals (NASDAQ:SNDX) Trading Down 7.4% Following Weak Earnings - MarketBeat
JPMorgan Chase & Co. Issues Positive Forecast for Syndax Pharmaceuticals (NASDAQ:SNDX) Stock Price - MarketBeat
Citigroup Issues Pessimistic Forecast for Syndax Pharmaceuticals (NASDAQ:SNDX) Stock Price - MarketBeat
Syndax Pharmaceuticals' (SNDX) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat
Syndax Pharmaceuticals Reports 2024 Financial Results - MSN
Syndax Pharmaceuticals Inc to Host Earnings Call - ACCESS Newswire
What is B. Riley’s Estimate for SNDX Q3 Earnings? - Defense World
What is HC Wainwright’s Forecast for SNDX FY2025 Earnings? - Defense World
Syndax Pharmaceuticals (NASDAQ:SNDX) Announces Quarterly Earnings Results - MarketBeat
Strong Buy Rating for Syndax Pharmaceuticals Driven by Revuforj’s Market Potential and Revenue Growth - TipRanks
HC Wainwright Reiterates “Buy” Rating for Syndax Pharmaceuticals (NASDAQ:SNDX) - Defense World
Syndax Pharmaceuticals (NASDAQ:SNDX) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says - Defense World
Syndax Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire
What is B. Riley’s Forecast for SNDX Q1 Earnings? - Defense World
What is HC Wainwright’s Forecast for SNDX Q1 Earnings? - Defense World
Syndax Pharmaceuticals Inc (SNDX) Q4 2024 Earnings Call Highlights: Strong Product Launch and ... By GuruFocus - Investing.com Canada
Syndax Pharmaceuticals’ Earnings Call Highlights Key Milestones - TipRanks
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - The Manila Times
Syndax Pharmaceuticals Inc (SNDX) Q4 2024 Earnings Call Highlights: Strong Product Launch and ... - Yahoo Finance
Rhumbline Advisers Reduces Holdings in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - Defense World
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(C)(4) - MENAFN.COM
Syndax Pharmaceuticals (NASDAQ:SNDX) Shares Down 7.4% on Disappointing Earnings - Defense World
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Q4 2024 Earnings Call Transcript - Insider Monkey
H.C. Wainwright maintains Buy on Syndax stock, $51 target - Investing.com
H.C. Wainwright maintains Buy on Syndax stock, $51 target By Investing.com - Investing.com UK
Decoding Syndax Pharmaceuticals Inc (SNDX): A Strategic SWOT Ins - GuruFocus.com
Goldman Sachs cuts Syndax stock price target to $31, maintains Buy - Investing.com
BTIG maintains Buy rating and $43 target on Syndax stock By Investing.com - Investing.com UK
Sanctuary Advisors LLC Cuts Stock Holdings in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - Defense World
Syndax Pharmaceuticals: Navigating Revenue Growth Amidst Regulatory and Market Challenges - TipRanks
Syndax: Q4 Earnings Snapshot - The Washington Post
Syndax Pharmaceuticals (SNDX) Reports Q4 Loss, Lags Revenue Estimates - MSN
B.Riley cuts Syndax stock target to $29, maintains Buy rating - Investing.com
Syndax projects $750M market opportunity for Revuforj driven by new launches and label expansions - MSN
Earnings call transcript: Syndax Pharmaceuticals misses forecasts, stock rises in Q4 2024 - Investing.com Canada
0.49%
1.87%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):